000788，董事长被刑拘

Core Viewpoint - The announcement from Peking University Medicine Co., Ltd. indicates that the chairman and president, Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties. The company asserts that its control, board operations, and financial management remain normal [3][4][5]. Group 1: Company Management Changes - On October 25, the company disclosed that Xu Xiren authorized board member Chen Yuezhong to act as chairman and executive vice president Yu Mengchuan to act as president and legal representative due to his inability to perform his duties [5][7]. - The company has established a robust governance structure and internal control mechanisms to ensure compliance with relevant laws and regulations during this transition [5]. Group 2: Company Background - Peking University Medicine has over 50 years of pharmaceutical manufacturing history and offers a wide range of products, including over 100 varieties across 10 major categories such as anti-tumor and cardiovascular drugs [12]. - The company was originally founded in 1965 and successfully listed on the Shenzhen Stock Exchange in 1997. It became a member of the New Fangzheng Group after a change in control in 2022 [12]. - Xu Xiren became the actual controller of the company in December 2024 after acquiring a 22.22% stake through a symbolic price transaction and debt assumption [12]. Group 3: Relationship with Peking University - As of August 2023, Peking University no longer has any direct relationship with the company, having undergone two rounds of actual controller changes since December 2022 [8]. - The company is in the process of gradually changing its name to reflect this separation from Peking University [8]. Group 4: Xu Xiren's Profile - Xu Xiren, born in April 1979, has a master's degree and has held various positions, including chairman and general manager of New Advantage Industry Group [8][9]. - He has connections to numerous enterprises across various sectors, including investment and public relations [9].